Hengsai Biological DC Vaccine Project Landed in Lecheng Pioneer Zone

On the morning of August 30, 2025, the Policy Promotion Meeting for New Biomedical Technologies in LeCheng Advanced Zone and the First Batch of Enterprises Concentrated Signing Conference were held in Boao LeCheng Never Ending International Innovative Pharmaceutical and Device Exhibition. Hainan Provincial People's Government, Hainan Provincial Department of Industry and Information Technology, Hainan Provincial Healthcare Commission, Hainan Provincial Medical Insurance Bureau, Hainan Provincial Pharmaceutical Administration, Hainan International Economic and Development Bureau, Lecheng Advanced Zone Management Bureau, Qionghai Municipal People's Government, Lecheng Medical Institutions and Biomedical Enterprises were present to witness the event.

In this conference, LCCA reached signing cooperation with 13 domestic head biomedical enterprises. Mr. Cheng Xiangguo, co-founder and COO of Hengsai Bio, participated in the signing as a representative of the enterprises with approved projects.Marking the official landing of Hengsai Biological DC Vaccine Project in Lecheng Pioneering ZoneThe

As the only "special medical zone" in China and an important platform for the construction of Hainan's free trade portIn recent years, LeCheng has fully utilized the "Nine Articles of the State" and other special policies granted by the state, and gradually built up a whole chain service system covering the rapid introduction, clinical application, registration and approval, and production and manufacturing of international innovative medicines and devices. At the same time, actively grasp the medical science and technology revolution and new opportunities for industrial change.Taking the lead in the country in the clinical translation and application of new biomedical technologies such as cell therapy and gene editingThe

HSI's DC vaccine has a good safety profile, is widely used (treatment and prevention of recurrence), does not require pretreatment, can be administered on an outpatient basis, and has a low treatment cost, which is expected to improve clinical accessibility and patient compliance.It is a perfect fit with the policy of biomedical new technology industry in LeCheng Pioneer Zone.As the first batch of domestic enterprises authorized to carry out DC vaccine transformation and application in LeCheng, Hengsai Bio will combine its own development needs and LeCheng's policy and platform advantages in the future, and will deeply integrate with LeCheng Pilot Zone for common development.The

The company's pipeline in development are all autologous DC vaccines without any gene editing, with indications covering hematological and solid tumors.Core pipeline KSD-101 is the world's first DC vaccine targeting EBV broad-spectrum, and is also the first original DC vaccine in China to receive FDA IND approval.The

Relying on the independently constructed Eco-DC Vax platform, the company systematically integrates the four modules of antigen prediction, immunological validation, process optimization and quality control, and has the capability of"One drug, multiple targets" and platform extensibilityThe company has a comprehensive R&D and production base with a floor area of 6,300 square meters in Shanghai FTZ Lingang First Area. At present, there is a comprehensive R&D and production base with a floor area of 6,300 square meters and a production capacity of about 5,000 servings/year in Shanghai FTZ Lingang First Area, which is equipped with the industry's top facilities.Hard power from research to industrializationHengsai Bio. Since its establishment, Hengsai Bio has been upholding the principle of"Making painless cures for tumor patients."We aim to break down the technical barriers to industrialization and develop the world's first-in-class, safe, efficient and conveniently administered high-quality DC vaccine products with independent property rights, so as to provide the most effective and efficient vaccine forDiseases in need of effective clinical treatments, such as relapsed and refractory tumors, chronic viral infections, and autoimmune diseasesProvide new avenues and strategies for treatment.